AshiBio
PrivateLast Round
Series A
Jun 20, 2024
Total Funding Raised
$40M
Company Overview
AshiBio operates in Healthcare & Life Sciences and is based in Burlingame, California. Its latest recorded funding round was a Series A round in June 2024.
AshiBio is a biotechnology company that develops innovative therapies aimed at preventing symptoms and slowing disease progression for patients with rare bone and connective tissue disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AshiBio Comparables
Compare AshiBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ipsen | 75% | |
| Mereo BioPharma Group plc | 72% | |
| SiSaf Ltd | 71% |
For institutional investors. Book with your work email.
AshiBio Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
AshiBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Agent Capital | Series A |
| MPM BioImpact | Series A, Seed |
| Mirae Asset Venture Investment | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 20, 2026
Monthly visitors increased 32% MoM, reaching 2K.
- Jun 20, 2024
$40M round with participation from Mirae Asset and Agent Capital.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 1, 2026
Ashibio Inc reports clinical biomarker data from a legacy vantictumab study in patients with cancer at the 2026 ASBMR Annual Meeting.
- is_developingAug 19, 2026
Ashibio Inc is developing treatments for fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder.
For institutional investors. Book with your work email.
AshiBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about AshiBio's valuation, stock price, and market status.
Is AshiBio a public or private company?
AshiBio is a private company.
What is the current stock price of AshiBio?
AshiBio is a private company, so its shares have no public market price. Caplight tracks AshiBio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AshiBio worth (valuation)?
Valuation information for AshiBio is not publicly available.
Can I buy AshiBio stock?
AshiBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AshiBio's last funding round?
AshiBio's most recent funding round was Series A on June 20, 2024.
Who are the main investors in AshiBio?
Key investors in AshiBio include MPM BioImpact.
Will AshiBio IPO soon?
No public IPO plans have been announced for AshiBio.
How can I track AshiBio secondary market activity?
Caplight tracks bids, offers, and trades in AshiBio's shares on secondary markets.